RUNX1 regulates corepressor interactions of PU.1

Blood

Volumn 117, Issue 24, 2011, Pages 6498-6508

  Hu, Zhenbo ^a   Gu, Xiaorong ^a   Baraoidan, Kristine ^b   Ibanez, Vinzon ^b   Sharma, Arun ^c   Kadkol, ShriHari ^b   Munker, Reinhold ^d   Ackerman, Steven ^b   Nucifora, Giuseppina ^b   Saunthararajah, Yogen ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTINOSTAT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; HISTONE DEACETYLASE 2; TRANSCRIPTION FACTOR PU 1; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR SIN3A; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE ACTIVATION; LEUKEMIA CELL; MACROPHAGE; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

EID: 79959197169     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-312512     Document Type: Article

References (50)

1. Niimi H, Harada H, Harada Y, et al. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia. 2006;20(4):635-644.
2. Miyoshi H, Shimizu K, Kozu T, et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A. 1991;88(23):10431-10434. (Pubitemid 21915849)
3. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84(2):321-330. (Pubitemid 26042836)
4. Elagib KE, Racke FK, Mogass M, et al. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 2003; 101(11):4333-4341. (Pubitemid 36857797)
5. Waltzer L, Ferjoux G, Bataille L, Haenlin M. Cooperation between the GATA and RUNX factors Serpent and Lozenge during Drosophila hematopoiesis. EMBO J. 2003;22(24):6516-6525. (Pubitemid 38009599)
6. Huang H, Yu M, Akie TE, et al. Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. Mol Cell Biol. 2009;29(15):4103-4115.
7. Zhang DE, Hetherington CJ, Meyers S, et al. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol. 1996;16(3):1231- 1240. (Pubitemid 26061693)
8. Petrovick MS, Hiebert SW, Friedman AD, et al. Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol Cell Biol. 1998;18(7):3915-3925. (Pubitemid 28287915)
9. Kim WY, Sieweke M, Ogawa E, et al. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J. 1999;18(6):1609-1620. (Pubitemid 29127073)
10. Goetz TL, Gu TL, Speck NA, Graves BJ. Autoinhibition of Ets-1 is counteracted by DNA binding cooperativity with core-binding factor alpha2. Mol Cell Biol. 2000;20(1):81-90. (Pubitemid 30002550)
11. Puig-Kroger A, Sanchez-Elsner T, Ruiz N, et al. RUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements. Blood. 2003;102(9): 3252-3261. (Pubitemid 37314764)
12. Smith LT, Hohaus S, Gonzalez DA, Dziennis SE, Tenen DG. PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood. 1996; 88(4):1234-1247. (Pubitemid 26276798)
13. Tagoh H, Ingram R, Wilson N, et al. The mechanism of repression of the myeloid-specific c-fms gene by Pax5 during B lineage restriction. EMBO J. 2006;25(5):1070-1080. (Pubitemid 43372120)
14. Huang G, Zhang P, Hirai H, et al. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet. 2008;40(1):51-60.
15. Iida H, Towatari M, Iida M, et al. Protein expression and constitutive phosphorylation of hematopoietic transcription factors PU.1 and C/EBP beta in acute myeloid leukemia blasts. Int J Hematol. 2000;71(2):153-158.
16. Kanno T, Kanno Y, Chen LF, et al. Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit. Mol Cell Biol. 1998; 18(5):2444-2454. (Pubitemid 28183414)
17. Suzuki M, Yamada T, Kihara-Negishi F, Sakurai T, Oikawa T. Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression. Oncogene. 2003;22(54):8688-8698. (Pubitemid 38010492)
18. Yamamoto H, Kihara-Negishi F, Yamada T, Hashimoto Y, Oikawa T. Physical and functional interactions between the transcription factor PU.1 and the coactivator CBP. Oncogene. 1999;18(7): 1495-1501. (Pubitemid 29103637)
19. Kihara-Negishi F, Yamamoto H, Suzuki M, et al. In vivo complex formation of PU.1 with HDAC1 associated with PU.1-mediated transcriptional repression. Oncogene. 2001;20(42):6039-6047. (Pubitemid 32955046)
20. Chakraborty S, Sinha KK, Senyuk V, Nucifora G. SUV39H1 interacts with AML1 and abrogates AML1 transactivity: AML1 is methylated in vivo. Oncogene. 2003;22(34):5229-5237. (Pubitemid 37056085)
21. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science. 1994;265(5178):1573-1577.
22. Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet. 2004;36(6):624-630. (Pubitemid 38715991)
23. Lamandin C, Sagot C, Roumier C, et al. Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? Blood. 2002;100(13): 4680-4681. (Pubitemid 35429718)
24. Vegesna V, Takeuchi S, Hofmann WK, et al. C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk Res. 2002; 26(5):451-457. (Pubitemid 34251089)
25. Mueller BU, Pabst T, Osato M, et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood. 2002;100(3):998-1007. (Pubitemid 34832629)
26. Walsh JC, DeKoter RP, Lee HJ, et al. Cooperative and antagonistic interplay between PU.1 and GATA-2 in the specification of myeloid cell fates. Immunity. 2002;17(5):665-676. (Pubitemid 35351511)
27. Munker R, Nordberg ML, Veillon D, et al. Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH). Leuk Res. 2009; 33(10):1405-1408.
28. Sun W, Downing JR. Haploinsufficiency of AML1 results in a decrease in the number of LTR-HSCs while simultaneously inducing an increase in more mature progenitors. Blood. 2004;104(12): 3565-3572. (Pubitemid 39564428)
29. Ibanez V, Sharma A, Buonamici S, et al. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation. Cancer Res. 2004;64(13):4547-4554. (Pubitemid 38856927)
30. Radtke I, Mullighan CG, Ishii M, et al. Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A. 2009;106(31):12944-12949.
31. Hohaus S, Petrovick MS, Voso MT, et al. PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. Mol Cell Biol. 1995; 15(10):5830-5845.
32. Carey M. The enhanceosome and transcriptional synergy. Cell. 1998;92(1):5-8. (Pubitemid 28053292)
33. Merika M, Williams AJ, Chen G, Collins T, Thanos D. Recruitment of CBP/p300 by the IFN beta enhanceosome is required for synergistic activation of transcription. Mol Cell. 1998;1(2): 277-287. (Pubitemid 128378668)
34. Senger K, Merika M, Agalioti T, et al. Gene repression by coactivator repulsion. Mol Cell. 2000; 6(4):931-937.
35. Osborne AR, Zhang H, Fejer G, et al. Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. J Biol Chem. 2004;279(28):28911-28919. (Pubitemid 38915759)
36. Linderson Y, Eberhard D, Malin S, et al. Corecruitment of the Grg4 repressor by PU.1 is critical for Pax5-mediated repression of B-cell-specific genes. EMBO Rep. 2004;5(3):291-296. (Pubitemid 38500110)
37. Coffman JA. Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biol Int. 2003;27(4):315-324. (Pubitemid 36638332)
38. Tanaka T, Tanaka K, Ogawa S, et al. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J. 1995;14(2):341-350.
39. Gutierrez-Angulo M, Gonzalez-Garcia JR, Meza-Espinoza JP, et al. Increased expression of AML1-a and acquired chromosomal abnormalities in childhood acute lymphoblastic leukemia. Hematol Oncol. 2005;22(3):85-90.
40. Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 1999; 59(12):2766-2769. (Pubitemid 29283104)
41. Lasa A, Nomdedeu JF, Carnicer MJ, Llorente A, Sierra J. ETO sequence may be dispensable in some AML1-ETO leukemias. Blood. 2002; 100(12):4243-4244. (Pubitemid 35396897)
42. Yan M, Kanbe E, Peterson LF, et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med. 2006;12(8):945-949. (Pubitemid 44175147)
43. Heller PG, Glembotsky AC, Gandhi MJ, et al. Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. Blood. 2005;105(12):4664-4670. (Pubitemid 40807286)
44. Hu Z, Negrotto S, Gu X, et al. Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. Mol Cancer Ther. 2010;9(6):1536-1543.
45. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst. 1998;90(21):1621-1625. (Pubitemid 28523436)
46. Kosugi H, Towatari M, Hatano S, et al. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia. 1999;13(9):1316-1324. (Pubitemid 29429756)
47. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood. 2009;113(16):3655-3665.
48. Milhem M, Mahmud N, Lavelle D, et al. Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A. Blood. 2004; 103(11):4102-4110. (Pubitemid 38685350)
49. Bug G, Gul H, Schwarz K, et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res. 2005;65(7): 2537-2541. (Pubitemid 40490047)
50. De Felice L, Tatarelli C, Mascolo MG, et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res. 2005;65(4): 1505-1513. (Pubitemid 40270180)